This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20® Serotypes matterBurden of diseaseIPDCAPPatient profilesPatient
profilesAge 50+: Arlene, Age 51Diabetes: David, Age 46Asthma: Carly, Age 30COPD: William, Age 48Age 65+: Tyrell, Age 67 Risk for All Underlying Medical ConditionsMary, 65: Healthy ≥65; Unknown Vaccination HistoryCDC recommendationsClinical studiesClinical studiesBuilt on PCV13CAPiTAStudy 1 designStudy 1 resultsStudy 1 safetyStudy 6 designStudy 6 resultsStudy 6 safetyAdministrationAccess & supportAccess & supportMedicareCommercial health plansMaterialsVideosEvents
Prescribing InformationIndicationsPatient SiteOrder Prevnar 20®
DiabetesDavid, age 46DIABETES puts adult patients at greater risk1,2~38.1 million US adults aged 18 years or older were living with diabetes in 20213*

2.9x greater risk for pneumococcal pneumonia compared with healthy adults in the same age range.4,5

1.9x more likely to die from IPD.2†‡

The CDC recommends Prevnar 20® for eligible adult patients with diabetes.6

Both vaccine-naïve§ and previously vaccinated eligible adults who are at an increased risk.6

Patients with chronic conditions# who have received PPSV23 only or PCV13 only are eligible for PCV20 or PCV21.6

The ADA recommends vaccinating adults with diabetes against pneumococcal disease.7

2.9x greater risk for pneumococcal pneumonia compared with healthy adults in the same age range.4,5


1.9x more likely to die from IPD.2†‡


The CDC recommends Prevnar 20® for eligible adult patients with diabetes.6


Both vaccine-naïve§ and previously vaccinated eligible adults who are at an increased risk.6


Patients with chronic conditions# who have received PPSV23 only or PCV13 only are eligible for PCV20 or PCV21.6


The ADA recommends vaccinating adults with diabetes against pneumococcal disease.7

5.3x greater risk for pneumococcal pneumonia.1,2*

1.9x† more likely to die from IPD.3‡

References*Vs healthy adults in the same age range.1,2

Prevnar 20® completes the CDC recommendation in one dose for ALL eligible adult patients.6,8 Vaccinate today.

Prevnar 20® completes the CDC recommendation in one dose for ALL eligible adult patients.6,8 Vaccinate today.

View risk data for pneumococcal pneumonia View risk chart LoadingPatient ProfilesDownload CDC recommendations for 50+ DownloadLoadingOrder Prevnar 20 for your office by registering for Prime Get startedLoadingReferencesADA=American Diabetes Association; CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease; ICU=intensive care unit; IPD=invasive pneumococcal disease; PCV7=7-valent pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; PCV21=21-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.*Data from National Health and Nutrition Examination Survey from January 2017 through March 2020. Diagnosed diabetes was based on self-reporting and undiagnosed diabetes was based on fasting plasma glucose and A1C levels among people self-reporting no diabetes.3†Based on a multicenter, observational cohort study on the prospective Outcomerea database, which contains data from 20 ICUs in France. Vaccination status and serotype information were not collected.2‡Than those without diabetes.2§Also applies to people who received PCV7 at any age and have received no other pneumococcal vaccines.6#Chronic conditions include alcoholism, chronic heart disease (including congestive heart failure and cardiomyopathies), chronic liver disease, chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma), cigarette smoking, and diabetes mellitus.6References:Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793-798. Garrouste-Orgeas M, Azoulay E, Ruckly S, et al. Diabetes was the only comorbid condition associated with mortality of invasive pneumococcal infection in ICU patients: a multicenter observational study from the Outcomerea research group. Infection. 2018;46(5):669-677. Centers for Disease Control and Prevention. National diabetes statistics report. May 15, 2024. Accessed November 7, 2024. https://www.cdc.gov/diabetes/php/data-research/index.htmlGrant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10(5):ofad192. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile supplementary data. Open Forum Infect Dis. 2023;10(5):S1-S35.Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. October 2024. Accessed November 3, 2024. https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes—2024. Diabetes Care. 2024;47(suppl 1):S52-S76. Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.ReferencesADA=American Diabetes Association; CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease; ICU=intensive care unit; IPD=invasive pneumococcal disease; PCV7=7-valent pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; PCV21=21-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.*Data from National Health and Nutrition Examination Survey from January 2017 through March 2020. Diagnosed diabetes was based on self-reporting and undiagnosed diabetes was based on fasting plasma glucose and A1C levels among people self-reporting no diabetes.3†Based on a multicenter, observational cohort study on the prospective Outcomerea database, which contains data from 20 ICUs in France. Vaccination status and serotype information were not collected.2‡Than those without diabetes.2§Also applies to people who received PCV7 at any age and have received no other pneumococcal vaccines.6#Chronic conditions include alcoholism, chronic heart disease (including congestive heart failure and cardiomyopathies), chronic liver disease, chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma), cigarette smoking, and diabetes mellitus.6References:Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793-798. Garrouste-Orgeas M, Azoulay E, Ruckly S, et al. Diabetes was the only comorbid condition associated with mortality of invasive pneumococcal infection in ICU patients: a multicenter observational study from the Outcomerea research group. Infection. 2018;46(5):669-677. Centers for Disease Control and Prevention. National diabetes statistics report. May 15, 2024. Accessed November 7, 2024. https://www.cdc.gov/diabetes/php/data-research/index.htmlGrant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10(5):ofad192. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile supplementary data. Open Forum Infect Dis. 2023;10(5):S1-S35.Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. October 2024. Accessed November 3, 2024. https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes—2024. Diabetes Care. 2024;47(suppl 1):S52-S76. Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Manufactured by Wyeth Pharmaceuticals LLC.

Marketed by Pfizer Inc.

PP-PNR-USA-2559 © 2025 Pfizer Inc.
All rights reserved. January 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2559
You are now leaving PfizerPro You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-MCL-USA-0367
INDICATIONS AND SELECT SAFETY INFORMATION
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

SELECT SAFETY INFORMATION
 
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
  • For Prevnar 20® in individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age
  • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.

Please click for Prevnar 13® Full Prescribing Information.INDICATIONS
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine